Advanced Biomedical Research
The effect of Vitamin B6 in the prevention of hematological adverse effects of linezolid in patients with chronic osteomyelitis: A randomized double-blind placebo-controlled clinical trial
Document Type : Original Article
Authors
- Kiana Shirani 1
- Farzin Khorvash 1
- Rasool Soltani 2
- Behrooz Ataie 1
- Mohammad Javad Tarrahi 3
- Farideh Fallah 4
1 Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
2 Infectious Diseases and Tropical Medicine Research Center; Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran
4 Department of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Background: Due to the contradictory results of the effects of Vitamin B6 in reducing the hematotoxic effects of linezolid, the present study aimed to investigate the possible role of Vitamin B6 administration in reducing linezolid-related hematological toxicities in patients with chronic osteomyelitis. Materials and Methods: In a randomized double-blind placebo-controlled clinical trial, patients with chronic osteomyelitis were randomly divided into two groups (n = 40 each): the intervention group received Vitamin B6 40 mg twice daily from the beginning of treatment with linezolid and the control group received placebo with linezolid, both for 21 days. Blood variables including hemoglobin (Hb), white blood cells (WBC), and platelets (PLT) were measured at baseline and at the end of the 1st, 2nd, and 3rd weeks (days 7, 14, and 21) of the intervention. Results: There was no significant difference between the groups regarding the count of WBC and PLT and level of Hb at evaluated time points. Furthermore, there was a significant decreasing trend in all parameters within both groups; however, the decreasing trend of both PLT and WBC was slower in the intervention (Vitamin B6) group compared to the placebo group. Conclusion: Vitamin B6 has no significant effect in the reduction of hematological adverse effects of linezolid in chronic osteomyelitis patients. However, it could retard the decreasing trend of WBC and PLT counts.
Keywords
| 1. |
Urish KL, Cassat JE. Staphylococcus aureus osteomyelitis: Bone, bugs, and surgery. Infect Immun 2020;88:e00932-19.  |
| 2. |
Hedrich CM, Morbach H, Reiser C, Girschick HJ. New insights into adult and paediatric chronic non-bacterial osteomyelitis CNO. Curr Rheumatol Rep 2020;22:52. |
| 3. |
Nasser A, Azimi T, Ostadmohammadi S, Ostadmohammadi S. A comprehensive review of bacterial osteomyelitis with emphasis on Staphylococcus aureus. Microb Pathog 2020;148:104431. |
| 4. |
Thitiananpakorn K, Aiba Y, Tan XE, Watanabe S, Kiga K, Sato'o Y, et al. Association of mprF mutations with cross-resistance to daptomycin and vancomycin in Methicillin-Resistant Staphylococcus aureus (MRSA). Sci Rep 2020;10:16107. |
| 5. |
Hashemian SM, Farhadi T, Ganjparvar M. Linezolid: A review of its properties, function, and use in critical care. Drug Des Devel Ther 2018;12:1759-67. |
| 6. |
Zahedi Bialvaei A, Rahbar M, Yousefi M, Asgharzadeh M, Samadi Kafil H. Linezolid: A promising option in the treatment of Gram-positives. J Antimicrob Chemother 2017;72:354-64. |
| 7. |
Nordmann P, Rodríguez-Villodres A, Poirel L. A selective culture medium for screening linezolid-resistant gram-positive bacteria. Diagn Microbiol Infect Dis 2019;95:1-4. |
| 8. |
Pratama NY, Zulkarnain BS, Soedarsono, Fatmawati U. Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy. J Basic Clin Physiol Pharmacol 2021;32:777-81. |
| 9. |
Sharma S, Syal A, Gupta M, Tahlan A, Kaur B. Reversible myelosuppresion with prolonged usage of linezolid in treatment of methicillin-resistant Staphylococcus aureus. Cureus 2020;12:e10890. |
| 10. |
Alsultan A. Determining therapeutic trough ranges for linezolid. Saudi Pharm J 2019;27:1061-3. |
| 11. |
Bayram N, Düzgöl M, Kara A, Özdemir FM, Devrim İ. Linezolid-related adverse effects in clinical practice in children. Arch Argent Pediatr 2017;115:470-5. |
| 12. |
Giunio-Zorkin N, Brown G. Real-life frequency of new-onset thrombocytopenia during linezolid treatment. Can J Hosp Pharm 2019;72:133-8. |
| 13. |
Plachouras D, Giannitsioti E, Athanassia S, Kontopidou F, Papadopoulos A, Kanellakopoulou K, Giamarellou H. No effect of pyridoxine on the incidence of myelosuppression during prolonged linezolid treatment. Clin Infect Dis 2006;43:e89-91. |
| 14. |
Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004;54:832-5. |
| 15. |
Kawakami T, Nakazawa H, Kawakami F, Matsuzawa S, Sudo Y, Sakai H, et al. Successful treatment of X-linked sideroblastic anemia with ALAS2 R452H mutation using vitamin B6. Rinsho Ketsueki 2018;59:401-6. |
| 16. |
Deng J, Su LX, Liang ZX, Liang LL, Yan P, Jia YH, et al. Effects of vitamin B6 therapy for sepsis patients with linezolid-associated cytopenias: A retrospective study. Curr Ther Res Clin Exp 2013;74:26-32. |
| 17. |
Youssef S, Hachem R, Chemaly RF, Adachi J, Ying J, Rolston K, et al. The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. J Antimicrob Chemother 2008;61:421-4.
|
)